Antinuclear autoantibodies in chronic schizophrenia

B. Spivak, M. Radwan, P. Bartur, R. Mester, A. Weizman*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


We determined the presence of antinuclear autoantibodies (ANA), antinative DNA and histone‐reactive ANA in 3 groups of chronic schizophrenic patients (n= 85): haloperidol‐treated patients (for at least 3 months) (n= 35), drug‐free for at least 3 months (n= 35) and neuroleptic‐naive patients (n= 15). The autoantibody titers were compared with those of healthy controls (n= 37). A significantly higher frequency of positive ANA was found among chronic schizophrenic patients (∼20%) as compared with the controls (∼5 %), irrespective of drug treatment, sex and age. No antinative ANA autoantibodies or histone reactive ANA were detected in either schizophrenic patients or controls. Further studies are needed to isolate and characterize in ANA‐positive schizophrenic patients 1 a putative specific ANA profile.

Original languageEnglish
Pages (from-to)266-269
Number of pages4
JournalActa Psychiatrica Scandinavica
Issue number4
StatePublished - Oct 1995


  • antinuclear autoantibodies
  • autoimmunity
  • schizophrenia


Dive into the research topics of 'Antinuclear autoantibodies in chronic schizophrenia'. Together they form a unique fingerprint.

Cite this